-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Sagimet Biosciences, Raises Price Target to $56

Benzinga·08/12/2026 15:56:07
Listen to the news
Canaccord Genuity analyst Edward Nash maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and raises the price target from $49 to $56.